Pelthos Therapeutics financials
$21.25−4.24%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $15.6M | $10.9M | $9.4M | $7.4M |
| Gross profit | $12.0M | $9.2M | $7.7M | $5.1M |
| Gross margin | 76.9% | 84.7% | 82.2% | 68.7% |
| Operating income | -$17.3M | -$13.1M | -$12.0M | -$15.4M |
| Net income | -$23.4M | -$25.1M | -$21.7M | -$16.2M |
| Net margin | −150.1% | −229.9% | −230.7% | −219.3% |
| Diluted EPS | $-6.62 | $-7.57 | $-6.78 | $-5.30 |
| EBITDA | -$16.0M | -$11.6M | -$10.8M | -$14.3M |
| Operating cash flow | -$7.7M | -$13.1M | -$6.3M | -$15.3M |
| Free cash flow | -$7.7M | -$13.3M | -$6.4M | -$15.3M |
| Diluted shares | 3.5M | 3.3M | 3.2M | 3.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $24.2M | $32.0M | $18.0M | $14.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $69.9M | $65.5M | $31.4M | $0.00 |
| Total assets | $137.4M | $145.4M | $130.4M | $126.4M |
| Total liabilities | $138.9M | $126.1M | $91.5M | $68.2M |
| Shareholders' equity | -$1.5M | $19.3M | $38.9M | $58.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology